Home・Elenco Azioni・Alkermes PLC

Alkermes PLC

Aperta

SettoreSettore sanitario

50.54 3.02

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

48.9

Massimo

50.16

Metriche Chiave
By Trading Economics
Entrata	67M 501K
Vendite	103M 496M
P/E Media del settore	130.342 68.51
EPS	0.52
Margine di Profitto	0.101
Dipendenti	2,050
EBITDA	76M 54M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+15.68% upside

Dividendi
By Acuity
Utili prossimi	27 ott 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-480M 8.3B
Apertura precedente	47.52
Chiusura precedente	50.54

Notizie sul Sentiment di mercato

By Acuity

10%

90%

14 / 340 Classifica in Healthcare

Alkermes PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 ago 2026, 19:26 UTC

News

Alkermes Plc shares are lower today amid concerns over recent insider sales by executives, despite the company's gross margin of 80.22%.

3 ago 2026, 20:02 UTC

Alkermes shares are higher today, driven by significant gains in the overall market and major technology stocks, despite earlier session pullbacks.

31 lug 2026, 19:36 UTC

Alkermes Plc shares are lower today, impacted by declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

30 lug 2026, 19:58 UTC

Alkermes Plc shares are higher during Thursday's session, reflecting a broader recovery in tech shares despite remaining below the 20-day moving average.

29 lug 2026, 20:03 UTC

News

Macro Event

Shares declining despite price target increases from JP Morgan, Baird.

28 lug 2026, 20:02 UTC

News

Event

Alkermes Plc shares are lower after reporting second-quarter earnings of 0 cents per share, below the consensus estimate of 29 cents.

24 lug 2026, 19:46 UTC

Alkermes Plc shares are lower today, pulling back after an early high. No specific news has been identified to explain the decline.

22 lug 2026, 19:36 UTC

Alkermes Plc shares are lower today, despite an earlier session high, amid rising crude oil prices and concerns over potential supply disruptions.

21 lug 2026, 18:46 UTC

Alkermes shares are higher today, supported by improved market sentiment and renewed interest in AI stocks. The asset is trading near its one-month range high.

20 lug 2026, 22:01 UTC

Alkermes Plc shares declined after-market, retracing from earlier peaks. The asset is currently below its 20-day moving average.

Confronto tra pari

Modifica del prezzo

Alkermes PLC Previsione

Obiettivo di Prezzo

By TipRanks

15.68% in crescita

Previsioni per 12 mesi

Media 57.46 USD 15.68%

Alto 65 USD

Basso 38 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Alkermes PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

13 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 13 che hanno fornito valutazioni azionarie a Alkermes PLC - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

14 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.